| Ripretinib Combined With Surgery in Advanced GIST That Have Failed Imatinib Therapy: A Multicenter,Observational Study (NCT05354388) | Sichuan Provincial People's Hospital | 2021-10-01 |
| Oncogenetic Panel and Integrated Clinical Data Registry Study for Wild Type Gastrointestinal Stromal Tumor Patients (NCT04821895) | National Health Research Institutes, Taiwan | 2021-08-28 |
| Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis (NCT04557969) | National Cancer Institute (NCI) | 2020-12-18 |
| A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib (NCT04633122) | Zai Lab (Shanghai) Co., Ltd. | 2020-11-25 |
| A Study of HQP1351 in Patients With GIST or Other Solid Tumors (NCT03594422) | Ascentage Pharma Group Inc. | 2018-07-11 |
| A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) (NCT03158103) | Memorial Sloan Kettering Cancer Center | 2017-04-15 |
| A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors (NCT02452424) | Daiichi Sankyo | 2015-07-02 |
| Unifying Advanced Treatment With Advanced Imaging (NCT03404076) | Heidelberg University | 2014-12-01 |
| Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor (NCT03440515) | Asan Medical Center | 2014-08-01 |
| Circulating Cell-free Tumor DNA in the Plasma of Patients With Gastrointestinal Stromal Tumors (GIST) (NCT02443948) | Fondazione del Piemonte per l'Oncologia | 2014-06-01 |
| MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) (NCT01991379) | Memorial Sloan Kettering Cancer Center | 2013-11-01 |
| LRG GIST Patient Registry (NCT07697248) | The Life Raft Group | 2013-04-01 |
| A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors (NCT01316263) | Eli Lilly and Company | 2011-08-01 |
| Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST) (NCT01391611) | Kristen Ganjoo | 2011-07-01 |
| A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST (NCT01294202) | Astex Pharmaceuticals, Inc. | 2011-03-01 |
| Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) (NCT00867113) | Novartis Pharmaceuticals | 2009-07-22 |
| Advanced Gastrointestinal Endoscopic Imaging (NCT01034670) | Stanford University | 2009-06-01 |
| A Study of Nilotinib Versus Imatinib in GIST Patients (NCT00785785) | Novartis Pharmaceuticals | 2009-03-01 |
| Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma (NCT00780494) | Stanford University | 2009-02-01 |
| B-Receptor Signaling in Cardiomyopathy (NCT01135849) | Daniel Bernstein | 2008-11-01 |
| Permission to Collect Blood Over Time for Research (NCT00767234) | Stanford University | 2008-08-01 |
| Trial of Dasatinib in Advanced Sarcomas (NCT00464620) | Sarcoma Alliance for Research through Collaboration | 2007-05-01 |
| A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen (NCT00623831) | Ludwig Institute for Cancer Research | 2007-05-01 |
| Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma (NCT01048281) | Stanford University | 2002-08-01 |